Press Release Archives - Break Through Cancer

February 3, 2026February 4, 2026

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers $12 million awarded to six collaborative teams developing new approaches to the earlier detection and diagnosis of pancreatic, ovarian, and esophageal cancers News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. In partnership with the American Association for Cancer Research (AACR), Lustgarten Foundation,......

December 11, 2025February 10, 2026

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells A multi-site trial pairs targeted therapy with next-generation MRD testing to track residual disease and uncover vulnerabilities in leukemia cells News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) December 11, 2025 – Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years despite advances in therapy. Even when patients achieve remission, the disease often returns, fueled by a small number of leukemia cells that survive initial treatment, known as measurable residual disease (MRD). These remaining......

October 8, 2025October 8, 2025

Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy

Real-Time Biopsies Uncover Hidden Response to Glioblastoma Therapy Early clinical trial results show that serial brain biopsies reveal immune activity in brain cancer not captured by standard scans News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 08, 2025 – A new study led by Break Through Cancer’s Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy, CAN-3110, triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI, according to early analyses of two patients with recurrent GBM. Published today in Science Translational Medicine,......

October 1, 2025October 1, 2025

New Blood-Based Technology Tracks Tumor Evolution in Ovarian Cancer Patients

New Blood-Based Technology Tracks Tumor Evolution in Ovarian Cancer Patients Break Through Cancer researchers uncover hidden cell populations driving relapse — findings could pave the way for more targeted treatments News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 01, 2025 – A new study published in Nature uncovers how ovarian cancers evolve during treatment, and how blood samples taken throughout disease progression could help guide therapies more effectively. The research shows that drug-resistant cancer cell populations may exist long before treatment begins, and that tracking these populations over time can reveal vulnerabilities that may be......

September 25, 2025January 26, 2026

American Cancer Society and Break Through Cancer Unite to Outsmart Ovarian Cancer

American Cancer Society and Break Through Cancer Unite to Outsmart Ovarian Cancer In recognition of Ovarian Cancer Awareness Month, two leading cancer research organizations to collaborate to bring decades of scientific research into clinical practice News Release For Immediate Release Media Contact: Michele Money-Carson, Michele.Money-Carson@cancer.org Kari McHugh, kari.mchugh@breakthroughcancer.org ATLANTA, September 25, 2025 – More than 20,000 new cases of ovarian cancer will be diagnosed in the United States this year, and more than 12,000 women are expected to die from the disease. Today, the American Cancer Society (ACS) and Break Through Cancer are announcing a strategic collaboration that will aim......

September 18, 2025September 26, 2025

Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research

Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) September 18, 2025 – Supported by patient-driven foundations, eight leading research institutions, including over 20 researchers, and a $15 million dollar investment, Break Through Cancer’s Defying Osteosarcoma TeamLab mobilizes the largest, most unified effort in pediatric osteosarcoma research in North America. While other cancers have benefited from waves of innovation and precision medicine, the standard chemotherapy treatment......

August 1, 2025October 17, 2025

New Study Finds Hidden Disease in Nearly Half of Ovarian Cancer Patients in ‘Remission’

New Study Finds Hidden Disease in Nearly Half of Ovarian Cancer Patients in ‘Remission’ Using minimally invasive surgery and blood tests Break Through Cancer TeamLab found cancer cells, new drug targets, and biological clues for future therapies News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) August 01, 2025 – Survival rates for advanced ovarian cancer have remained stagnant for over four decades, largely because it so often recurs. While patients respond well to initial surgery and chemotherapy, it comes back in 4 out of 5 cases. A new Break Through Cancer study published in Clinical Cancer......

July 10, 2025October 1, 2025

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach Scientists are exploring if early intervention can prevent AML in high-risk patients, shifting the focus from monitoring to proactive prevention News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) July 10, 2025 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of early intervention for Clonal Hematopoiesis (CH), a precursor to acute myeloid leukemia (AML). This multi-institutional study focuses on high-risk patients, exploring a new approach to managing this pre-malignant......

April 30, 2025October 1, 2025

Small Biopsies, Big Insights: How Tiny Tissue Samples Could Transform Glioblastoma Research

Small Biopsies, Big Insights: How Tiny Tissue Samples Could Transform Glioblastoma Research New study from Break Through Cancer TeamLab unveils the power of investigational biopsies, unlocking a promising tool for real-time monitoring of glioblastoma News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) April 30, 2025 – Glioblastoma (GBM) is a highly aggressive form of brain cancer, leaving patients with limited treatment options. In a new study published in Nature Communications, the Break Through Cancer Accelerating GBM Therapies Through Serial Biopsies TeamLab has demonstrated how “investigative biopsies” can unlock critical insights into tumor biology. To address the......

December 18, 2024October 1, 2025

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org Collaboration with Revolution Medicines to Study Biomarkers for RAS(ON) Multi-Selective Inhibitor in Pancreatic Cancer The expanded phase 1 clinical trial is using serial biopsies and blood samples to analyze the tumor response to RMC-6236 at an unprecedented level of detail. (CAMBRIDGE, MASS.) December 19, 2024 – Break Through Cancer has launched a collaborative cohort for a Phase 1 study of RMC-6236, a compound developed by Revolution Medicines that is designed to suppress multiple......